Worth reading
75Important
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFiscal year ending March 202611 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥11,236 million+13.4%
Operating profit¥1,668 million+28.3%
Ordinary income¥1,717 million+31.8%
Net income¥1,070 million+6.6%
Gross Profit Margin46.7 %
Operating profit margin14.8 %
Selling, general and administrative expenses¥3,574 million
Full-year earnings forecast
Fiscal year ending March 2027
Net Sales
¥10,300 million
Gross profit
¥4,841 million
Selling, general and administrative expenses
¥3,736 million
Operating profit
¥1,105 million
Ordinary income
¥1,105 million
Net income
¥773 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Net Sales
Blood collection tube preparation equipment and systems+¥1,256 million
Specimen Testing Equipment-¥94 million
Consumables and other products+¥169 million
Operating profitSignificant decrease in research and development expenses, increase in gross profit, etc. (individual amounts not disclosed)
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
The materials state that the outlook was prepared based on certain assumptions, but specific figures for foreign exchange rates, raw material prices and other factors were not disclosedNew initiatives
- Build a business model centered on RFID for blood collection tube preparation equipment and systems
- Expand subscriptions for systems, software and cloud-related products
- Introduce automated blood collection table systems overseas
- Roll out new models including ROBO-9000, UA・ROBO and u-TRIPS
- Change the dividend policy to target a dividend payout ratio of at least 80% and a total payout ratio of 150%
Key KPIsA metric the company considers important as a management benchmark.
- Number of facilities using blood collection tube preparation equipment and systems489 FacilityYear on year against the same period last year+59 facilities
- Number of new facilities in Japan103 FacilityYear on year against the same period last year-6 facilities
- Number of facilities in Japan receiving replacement equipment227 FacilityYear on year against the same period last year+94 facilities
- Number of overseas facilities159 FacilityYear on year against the same period last year-29 facilities
- Number of facilities using TRIPS166 FacilityYear on year against the same period last year+19 facilities
- Overseas revenue ratio12.8 %Year on year against the same period last year-1.0pt
- ROE7.4 %Year on year against the same period last year+0.3pt
- PBR (fiscal year-end)1.08 times
- PER (fiscal year-end)15.06 times
Segment results
Blood collection tube preparation equipment and systems
Net Sales¥4,892 million
Year on year against the same period last year+¥1,256 million
Specimen Testing Equipment
Net Sales¥528 million
Year on year against the same period last year-¥94 million
Consumables and other products
Net Sales¥5,817 million
Year on year against the same period last year+¥169 million
Medium-term management plan targets
Target fiscal yearFiscal year ending March 2028
Net Sales
112 Hundreds of millions of yen
Operating profit
14.8 Hundreds of millions of yen
ROE
7.7 %
2030 long-term vision
Net Sales
150 Hundreds of millions of yen
Operating profit
30 Hundreds of millions of yen
ROE
10 %
Financial targets
ROE
Actual results for the fiscal year ending March 20267.4%
Fiscal year ending March 2027: plan5.5%
Plan for the fiscal year ending March 20286.1%
2030 target10%
Cost of shareholders’ equity7%
Number of employees
Number of Employees239 People
Hiring planRecruitment focused primarily on people in their 20s, with the target number of hires not disclosed
Annual Dividend
Dividend amount¥860 million
Payout ratio
80 %
TargetAt least 80% for fiscal years ending March 2026 through March 2028
Total payout ratio150%
Acquisition of treasury shares
Acquisition amount¥675 million (actual for the fiscal year ending March 2026)
PolicyTo be conducted as necessary
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Net Sales | ¥11,236 million (YoY +13.4%) |
| Operating profit | ¥1,668 million (YoY +28.3%) |
| Ordinary income | ¥1,717 million (YoY +31.8%) |
| Net income | ¥1,070 million (YoY +6.6%) |
| Gross Profit Margin | 46.7 % |
| Operating profit margin | 14.8 % |
| Selling, general and administrative expenses | ¥3,574 million |
| Full-year earnings forecast | Subject Fiscal year ending March 2027 / Net Sales ¥10,300 million / Gross profit ¥4,841 million / Selling, general and administrative expenses ¥3,736 million / Operating profit ¥1,105 million / Ordinary income ¥1,105 million / Net income ¥773 million |
| Segment results | Blood collection tube preparation equipment and systems Net Sales ¥4,892 million / Year on year against the same period last year +¥1,256 million / Specimen Testing Equipment Net Sales ¥528 million / Year on year against the same period last year -¥94 million / Consumables and other products Net Sales ¥5,817 million / Year on year against the same period last year +¥169 million |
| Breakdown of Factors Affecting the Change | Net Sales Blood collection tube preparation equipment and systems +¥1,256 million / Specimen Testing Equipment -¥94 million / Consumables and other products +¥169 million / Operating profit Significant decrease in research and development expenses, increase in gross profit, etc. (individual amounts not disclosed) |
| Key KPIs | Indicator name Number of facilities using blood collection tube preparation equipment and systems / Value 489 Facility / Year on year against the same period last year +59 facilities, Indicator name Number of new facilities in Japan / Value 103 Facility / Year on year against the same period last year -6 facilities, Indicator name Number of facilities in Japan receiving replacement equipment / Value 227 Facility / Year on year against the same period last year +94 facilities, Indicator name Number of overseas facilities / Value 159 Facility / Year on year against the same period last year -29 facilities, Indicator name Number of facilities using TRIPS / Value 166 Facility / Year on year against the same period last year +19 facilities, Indicator name Overseas revenue ratio / Value 12.8 % / Year on year against the same period last year -1.0pt, Indicator name ROE / Value 7.4 % / Year on year against the same period last year +0.3pt, Indicator name PBR (fiscal year-end) / Value 1.08 times / Year on year against the same period last year Not disclosed, Indicator name PER (fiscal year-end) / Value 15.06 times / Year on year against the same period last year Not disclosed |
| Number of employees | Number of Employees 239 People / Change during the period Not disclosed / Hiring plan Recruitment focused primarily on people in their 20s, with the target number of hires not disclosed |
| Assumptions Underlying the Business Outlook | The materials state that the outlook was prepared based on certain assumptions, but specific figures for foreign exchange rates, raw material prices and other factors were not disclosed |
| Medium-term management plan targets | Target fiscal year Fiscal year ending March 2028 / Net Sales 112 Hundreds of millions of yen / Operating profit 14.8 Hundreds of millions of yen / ROE 7.7 % / 2030 long-term vision Net Sales 150 Hundreds of millions of yen / Operating profit 30 Hundreds of millions of yen / ROE 10 % |
| Financial targets | ROE Actual results for the fiscal year ending March 2026 7.4% / Fiscal year ending March 2027: plan 5.5% / Plan for the fiscal year ending March 2028 6.1% / 2030 target 10% / Cost of shareholders’ equity 7% |
| Annual Dividend | Annual dividend per share Not disclosed / Interim Not disclosed / End of period Not disclosed / Dividend amount ¥860 million |
| Payout ratio | 80 % |
| Acquisition of treasury shares | Acquisition amount ¥675 million (actual for the fiscal year ending March 2026) / Number of shares acquired Not disclosed / Period Not disclosed / Policy To be conducted as necessary |
| New initiatives | Build a business model centered on RFID for blood collection tube preparation equipment and systems, Expand subscriptions for systems, software and cloud-related products, Introduce automated blood collection table systems overseas, Roll out new models including ROBO-9000, UA・ROBO and u-TRIPS, Change the dividend policy to target a dividend payout ratio of at least 80% and a total payout ratio of 150% |
Items this document does not state (10)
Results for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ending March 2026, sales of blood collection tube preparation equipment and systems to large facilities in Japan and overseas increased, while consumables and other products also remained solid. Operating profit increased because there were fewer large-scale projects and research and development expenses declined significantly, while the gross profit margin fell due to narrower margins and inventory valuation losses on products. Net income grew less than operating profit because the Company recorded a ¥193 million provision for losses associated with the discontinuation of production of certain models of blood collection tube preparation equipment. For the fiscal year ending March 2027, the Company expects lower sales due to a decline in replacement demand for blood collection tube preparation equipment and systems, a decrease in gross profit, and higher selling, general and administrative expenses, including labor costs and research and development expenses.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.